Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR ...Middle East

STOCKHOLM, March 17, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that data from the company's leading program fostroxacitabine bralpamide...

Hence then, the article about medivir to present data on additive efficacy of fostrox in triple combination with anti pd1 and kinase inhibitor in nonclinical tumor models at aacr was published today ( Friday 17/03/2023 - 11:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR )

Also on site :

• Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled
• TIER IV secures Japanese government grant to advance autonomous bus field operational tests and talent development in Saudi Arabia
• WikiLeaks at 20: The leaks that shook the world (VIDEOS)